View Older Stories View More Recent Stories
-
After-hours movers: Apple, Amazon, Netflix, Reddit and more
-
Gilead Sciences (GILD) Tops Q3 EPS by 32c; offers guidance
-
Gilead Sciences (GILD) call put ratio 3.2 calls to 1 put into quarter results
-
Gilead Sciences (GILD) call put ratio 4.6 calls to 1 put into quarter results
-
Gilead to present liver disease data at AASLD conference
-
RBC on Gilead Sciences (GILD): 'Next-Gen HIV Drug Appears Terminated'
-
Gilead presents new HIV research data at European AIDS Conference
-
Gilead to present Trodelvy breast cancer data at ESMO 2025
-
Biotech stocks: Q3 earnings preview
-
Gilead Sciences (GILD) PT Raised to $100 at RBC Capital
-
Bernstein: 'A Clear Win For Gilead Sciences (GILD)'
-
Gilead stock rises after settling Biktarvy patent disputes
-
Gilead settles patent disputes over Biktarvy with generic drugmakers
-
Needham Reiterates Buy Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put with a focus on a spreader of October 115 and 118 calls
-
Gilead Sciences (GILD) Shares Drop After RBC Speculates On Biktarvy Price
-
RBC on Gilead Sciences (GILD): 'Could Biktarvy Be The $137 Pill Trump Wants To Cut To $18'
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Hanmi Pharm licenses oral drug delivery compound to Gilead Sciences
-
Gilead Sciences (GILD) PT Raised to $143 at Rothschild Redburn
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
Gilead partners with PEPFAR to deliver HIV prevention drug to 2 million people
-
Gilead Sciences (GILD) to offer lenacapavir to global fund, U.S. government's PEPFAR program “at cost” and without profit - U.S. State Dept
-
Gilead Sciences breaks ground on new manufacturing facility in Foster City
-
Gilead stock falls after CVS holds off adding HIV prevention shot to plans
-
BMO Capital on Gilead Sciences (GILD): 'Expect GILD shares to be weaker on this announcement'
-
CVS Health (CVS) not yet adding Gilead's Yeztugo to its commercial or ACA plans - Reuters
-
Gilead Sciences (GILD) PT Raised to $131 at Mizuho
-
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD)
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
Gilead Sciences (GILD) PT Raised to $140 at BofA Securities
-
Gilead Sciences (GILD) PT Raised to $98 at RBC Capital
-
Gilead Sciences (GILD) PT Raised to $115 at TD Cowen
-
Truist Securities Upgrades Gilead Sciences (GILD) to Buy
-
Gilead Sciences (GILD) PT Raised to $143 at Morgan Stanley
-
Gilead Sciences (GILD) PT Raised to $112 at UBS
-
Stocks expected to have increasing option volume: GILD MNST FLUT XYZ TEAM TTD TTWO PINS EXPE TWLO TXRH WYNN DOCS AKAM FROG YELP
-
Gilead Sciences (GILD) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY25 Guidance
-
Gilead Sciences (GILD) call put ratio 1 call to 1.1 put into tquarter results
-
Gilead Sciences (GILD) call put ratio 1.1 calls to 1 put into quarter results
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
Gilead Sciences stock falls amid reports of preventive health panel dismissal
-
Needham Upgrades Gilead Sciences (GILD) to Buy
-
Gilead receives positive EU opinion for twice-yearly HIV prevention drug
-
U.S. large biotech stocks Q2 earnings preview
-
NY AG James on X: My office and 48 AGs secured $202M from Gilead Sciences (GILD) over HIV medication kickbacks
-
Gilead presents data on twice-yearly HIV prevention drug at IAS 2025
-
Bernstein on Gilead Sciences (GILD): 'Yeztugo Launch Likely to Rocket, or More of a Slow Burn?'
-
Gilead extends gains after Supreme Court upheld an Obamacare provision
-
SCOTUS Braidwood ruling is favorable for Gilead Sciences (GILD) - Morgan Stanley
